ReviewWorld journal of gastroenterology2016
Combined hepatocellular cholangiocarcinoma: Controversies to be addressed.
Review in World journal of gastroenterology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed.
- Update on the clinical features, treatment and histogenesis of combined hepatocellular-cholangiocarcinoma.Oncology letters · 2026Article
- Establishment of a prognostic nomogram and risk stratification system for patients with combined hepatocellular-cholangiocarcinoma.Scientific reports · 2025Article
- Development and validation of a nomogram to predict prognosis of patients with combined hepatocellular-cholangiocarcinoma after hepatic resection.Journal of Cancer · 2025Article
- Combined hepatocellular carcinoma-cholangiocarcinoma with sarcomatoid features: new insights into a rare and aggressive tumor.Journal of gastrointestinal oncology · 2024Article
- Combined hepatocellular cholangiocarcinoma: A clinicopathological update.World journal of hepatology · 2024Review
- Non-invasive imaging in the diagnosis of combined hepatocellular carcinoma and cholangiocarcinoma.Abdominal radiology (New York) · 2023Review
- The Diagnostic Approach towards Combined Hepatocellular-Cholangiocarcinoma-State of the Art and Future Perspectives.Cancers · 2023Review
- Decreased ARG1 expression as an adverse prognostic phenotype in non-alcoholic non-virus-related hepatocellular carcinoma.Virchows Archiv : an international journal of pathology · 2022Article
- Component with abundant immune-related cells in combined hepatocellular cholangiocarcinoma identified by cluster analysis.Cancer science · 2022Article
- Survival outcomes of combined hepatocellular-cholangiocarcinoma compared with intrahepatic cholangiocarcinoma: A SEER population-based cohort study.Cancer medicine · 2022Article
- The Value of Contrast-Enhanced Magnetic Resonance Imaging Enhancement in the Differential Diagnosis of Hepatocellular Carcinoma and Combined Hepatocellular Cholangiocarinoma.Journal of oncology · 2022Article
- Prediction of Prognosis for cHCC-CC Patients After Surgery: Comparison of Tumor Marker Score Based on AFP, CEA, CA19-9, and Other Clinical Stages.Annals of surgical oncology · 2021Article
- Long-Term Survival of Combined Hepatocellular-Cholangiocarcinoma: A Nationwide Study.The oncologist · 2021Article
- Primary Combined Hepatocellular-Cholangiocarcinoma: A Case of Underdiagnosed Primary Liver Cancer.Cureus · 2021Article
- Locoregional Treatments in Cholangiocarcinoma and Combined Hepatocellular Cholangiocarcinoma.Cancers · 2021Review
- Hepatocellular carcinoma with biliary and neuroendocrine differentiation: A case report.World journal of clinical oncology · 2021Article
- Incidence, Predictors, and Mortality in Patients With Liver Cancer After Fontan Operation.Journal of the American Heart Association · 2021Article
- Intrahepatic Cholangiocarcinoma Cells Promote Epithelial-mesenchymal Transition of Hepatocellular Carcinoma Cells by Secreting LAMC2.Journal of Cancer · 2021Article
- Prediction of Survival and Analysis of Prognostic Factors for Patients With Combined Hepatocellular Carcinoma and Cholangiocarcinoma: A Population-Based Study.Frontiers in oncology · 2021Article
- Clinicopathological features and recurrence patterns of combined hepatocellular-cholangiocarcinoma.World journal of surgical oncology · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Combined hepatocellular cholangiocarcinoma (CHC) accounts for 0.4%-14.2% of primary liver cancer cases and possesses pathological features of both hepatocellular carcinoma and cholangiocarcinoma. Since this disease was first described and classified in 1949, the classification of CHC has continuously evolved. The latest definition and classification of CHC by the World Health Organization is based on the speculation that CHC arises from hepatic progenitor cells. However, there is no evidence demonstrating the common origin of different components of CHC. Furthermore, the definition of CHC subtypes is still ambiguous and the identification of CHC subtype when a single tumor contains many components has remained unresolved. In addition, there is no summary on the newly recognized histopathology features or the contribution of CHC components to prognosis and outcome of this disease. Here we provide a review of the current literature to address these questions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.